ATSIC 2016:新的结核皮肤试验C-Tb优于PPD试验

2016-05-18 Seven L 译 MedSci原创

美国胸学会2016国际会议称,一种新的潜伏结核皮肤测试不仅安全易使用,并解决了当前测试对接种BCG疫苗后出现假阳性的问题。基于抗原ESAT-6和CFP10,丹麦Statens Serum Intitut开发的新测试C-Tb。Statens Serum Institut的Morten Ruhwald博士说:“它结合了PPD结核菌素皮肤试验的优点,以及干扰素γ释放试验的高度特异性。”研究人员给出的数据

美国胸学会2016国际会议称,一种新的针对潜伏性结核的皮肤测试不仅安全易使用,并解决了当前测试对接种BCG疫苗后出现假阳性的问题。

基于抗原ESAT-6和CFP10,丹麦Statens Serum Intitut开发的新测试C-Tb。Statens Serum Institut的Morten Ruhwald博士说:“它结合了PPD结核菌素皮肤试验的优点,以及干扰素γ释放试验的高度特异性。”

研究人员给出的数据来自两个完成的3期临床试验,TESEC-05和TESEC-06。TESEC-05试验包含来自南非开普敦的1,090名结核病症状和100名对照参与者;TESEC-06试验包含西班牙加泰罗尼亚、加利西亚和巴斯克的13个临床试验地点的979名参与者,拥有结核杆菌感染的风险因素。

在这两项试验中,通过双盲方法对参与者的前臂进行C-Tb和结核菌素皮肤试验。2-3天后观察皮肤硬结情况。在皮肤试验之前对患者进行血液IGRA检测(Quantiferon, QFT-GIT)。

研究结果显示,与结核菌素皮肤试验相比,C-Tb的安全性是可以接受的。研究者对212名假定非暴露的西班牙对照组评估了检测的特异性,结果显示C-Tb与QFT-GIT的特异性具有可比性(均为97%, P = 1),并且不会受到BCG疫苗接种的影响。而目前的结核菌素皮肤试验对接种BCG疫苗和未接种人群的特异性分别为62%和95%(P < .001)。对于确诊结核的患者,C-Tb和QFT-GIT的敏感度也具有可比性(77% vs. 81%; P = .08)。此外,结核暴露与C-Tb测试阳性率的增加具有强烈的趋势。

原始出处:

Ruhwald M, et al. Diagnostic accuracy of the novel C-Tb skin test for latent M. tuberculosis infection: Results from two phase 3 clinical trials. Presented at the American Thoracic Society International Conference, May 13 to 18, 2016; San Francisco.

New TB skin test safe, easy to use.Healio.May 17, 2016


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2068188, encodeId=b5fd2068188c0, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Jun 03 22:44:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988487, encodeId=2f82198848e7e, content=<a href='/topic/show?id=f437e2116d6' target=_blank style='color:#2F92EE;'>#皮肤试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72116, encryptionId=f437e2116d6, topicName=皮肤试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu May 04 12:44:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130336, encodeId=c83113033699, content=不错哦继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 18 15:38:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86942, encodeId=2a528694223, content=多了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 24 15:49:00 CST 2016, time=2016-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86943, encodeId=563e86943ab, content=多学学?!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 24 15:49:00 CST 2016, time=2016-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253986, encodeId=ddea125398617, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri May 20 09:44:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2068188, encodeId=b5fd2068188c0, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Jun 03 22:44:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988487, encodeId=2f82198848e7e, content=<a href='/topic/show?id=f437e2116d6' target=_blank style='color:#2F92EE;'>#皮肤试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72116, encryptionId=f437e2116d6, topicName=皮肤试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu May 04 12:44:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130336, encodeId=c83113033699, content=不错哦继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 18 15:38:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86942, encodeId=2a528694223, content=多了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 24 15:49:00 CST 2016, time=2016-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86943, encodeId=563e86943ab, content=多学学?!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 24 15:49:00 CST 2016, time=2016-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253986, encodeId=ddea125398617, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri May 20 09:44:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2068188, encodeId=b5fd2068188c0, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Jun 03 22:44:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988487, encodeId=2f82198848e7e, content=<a href='/topic/show?id=f437e2116d6' target=_blank style='color:#2F92EE;'>#皮肤试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72116, encryptionId=f437e2116d6, topicName=皮肤试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu May 04 12:44:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130336, encodeId=c83113033699, content=不错哦继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 18 15:38:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86942, encodeId=2a528694223, content=多了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 24 15:49:00 CST 2016, time=2016-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86943, encodeId=563e86943ab, content=多学学?!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 24 15:49:00 CST 2016, time=2016-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253986, encodeId=ddea125398617, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri May 20 09:44:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
    2016-09-18 1e10c84am36(暂无匿称)

    不错哦继续关注

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2068188, encodeId=b5fd2068188c0, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Jun 03 22:44:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988487, encodeId=2f82198848e7e, content=<a href='/topic/show?id=f437e2116d6' target=_blank style='color:#2F92EE;'>#皮肤试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72116, encryptionId=f437e2116d6, topicName=皮肤试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu May 04 12:44:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130336, encodeId=c83113033699, content=不错哦继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 18 15:38:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86942, encodeId=2a528694223, content=多了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 24 15:49:00 CST 2016, time=2016-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86943, encodeId=563e86943ab, content=多学学?!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 24 15:49:00 CST 2016, time=2016-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253986, encodeId=ddea125398617, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri May 20 09:44:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
    2016-05-24 忠诚向上

    多了解

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2068188, encodeId=b5fd2068188c0, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Jun 03 22:44:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988487, encodeId=2f82198848e7e, content=<a href='/topic/show?id=f437e2116d6' target=_blank style='color:#2F92EE;'>#皮肤试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72116, encryptionId=f437e2116d6, topicName=皮肤试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu May 04 12:44:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130336, encodeId=c83113033699, content=不错哦继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 18 15:38:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86942, encodeId=2a528694223, content=多了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 24 15:49:00 CST 2016, time=2016-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86943, encodeId=563e86943ab, content=多学学?!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 24 15:49:00 CST 2016, time=2016-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253986, encodeId=ddea125398617, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri May 20 09:44:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
    2016-05-24 忠诚向上

    多学学?!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2068188, encodeId=b5fd2068188c0, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Jun 03 22:44:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988487, encodeId=2f82198848e7e, content=<a href='/topic/show?id=f437e2116d6' target=_blank style='color:#2F92EE;'>#皮肤试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72116, encryptionId=f437e2116d6, topicName=皮肤试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu May 04 12:44:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130336, encodeId=c83113033699, content=不错哦继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 18 15:38:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86942, encodeId=2a528694223, content=多了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 24 15:49:00 CST 2016, time=2016-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86943, encodeId=563e86943ab, content=多学学?!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 24 15:49:00 CST 2016, time=2016-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253986, encodeId=ddea125398617, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri May 20 09:44:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]

相关资讯

Thorax:维生素D缺乏与肺外结核的风险关系

背景:肺外结核越来越普遍,但对结核病的临床谱宽的决定因素了解甚少。方法:对国家的监察数据进行调查(英国伯明翰:1980-2009年和美国疾病控制中心:1993-2008年)以确定人口因素与肺外肺结核的相关性。研究者直接分析这些因素以及血清25- 羟胆骨化醇(25(OH)D)浓度与肺外结核的相关性,通过一个单独英国的队列多因素分析。结果:从伯明翰共纳入10152例肺结核患者,美国纳入277013例。

BMC Cancer:不同肺部疾病与不同类型肺癌间关系

有研究报道了不同肺部疾病(哮喘、慢性阻塞性肺疾病(COPD)和结核病(TB))与肺癌风险的联系,不过关于肺部疾病和不同组织学类型的肺癌风险联系的研究还没有。研究者纳入了台湾地区2004-2008年诊断为肺癌的患者,并通过相关数据库获取肺癌组织学类型。通过Cox风险比例模型计算哮喘、COPD、TB与不同组织学类型的肺癌间联系。研究期间,从 15,219,024 名人中共发生了32,759例肺癌(年龄

误诊为皮肤结核的豚鼠耳炎奴卡菌感染1例!

患者男性,30岁。因“右肘外伤12年,局部皮肤反复流脓6年”入院。1999年夏季骑摩托车摔倒,致右肘部皮肤破溃,就诊当地卫生所,予局部清创缝合后伤口愈合。2005年底原右肘部摔伤处皮肤出现一结节,无明显触痛,局部无发红。

Lancet:临床试验证实简单的尿液结核测试可降低HIV病人死亡率

根据一项新的研究,对HIV感染者进行一项低成本的操作简便的尿液测试用于诊断是否患有结核病(tuberculosis , TB)有助降低HIV阳性患者在医院的TB死亡率。

PLoS ONE:异烟肼预防性治疗可降低成年HIV感染者结核病发作风险

Dilla 大学健康科学和转诊医院公共健康部门Ayele HT和同事做了一项随机试验的系统回顾和荟萃分析,分析发现异烟肼预防性治疗具有降低成年HIV感染者结核病发作风险的作用。研究结果在PLoS ONE在线发表。